Tech

Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 23/10/2026, 00:28:24 UTC.

Briefings

Merck and Moderna announced a late-stage trial showing personalized mRNA vaccines against melanoma reduced death or recurrence by 42% compared to standard treatment. The company CEO stated this marks a defining moment for mRNA technology in cancer therapy, reinforcing the potential to fundamentally change cancer treatment paradigms. Regulatory authorities are currently engaged to seek approval for the vaccine.

Key points

• Merck and Moderna reported a 42% reduction in death or recurrence rates for melanoma patients receiving personalized mRNA vaccines versus standard treatments in a late-stage trial.
• The vaccine is currently undergoing regulatory review to obtain approval for clinical use.

Context

Merck and Moderna are developing personalized mRNA vaccines targeting melanoma, the deadliest form of skin cancer. Their success in this trial supports broader hopes that individualized cancer-targeting medicines will redefine cancer therapy approaches.

Limitations

The evidence is from a late-stage trial with a specific date of 2026-10-22. The study focuses only on melanoma patients, limiting generalizability to other cancer types. The 42% reduction is a specific finding from this trial, and the vaccine is not yet approved for general use.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 23/10/2026, 00:40:00 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeicci7yb6shwhqqg5c6kiim527z4ejpa47gpv2yzc5kjbhbsgfxlui